{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:10:16Z","timestamp":1793211016501,"version":"4.5.0"},"reference-count":30,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxics"],"abstract":"<jats:p>(1) Background: To investigate the risk factors associated with optic neuropathy (ON) and validate the hypothesis that concomitant isoniazid use and other causes of toxic ON affect the development of ON in ethambutol users. (2) Methods: This cohort study identified ethambutol users who initiated ethambutol therapy between January 2015 and December 2021 and had no ON prior to ethambutol therapy. ON incidence up to 31 December 2022 was evaluated. The users were grouped on the basis of the presence of ON. Demographic and clinical characteristics were investigated for risk factor analyses of ON. Odds ratios (ORs) were calculated using multivariate logistic regression analyses. (3) Results: Among 204,598 ethambutol users, 5277 (2.6%) patients developed ON over the study period. Patients with ON included a higher percentage of women and had a higher mean age than patients without ON. In the multivariate analyses, the risk factors for ON and visual impairment included sex, age, cumulative dose, extrapulmonary indications for ethambutol use, and systemic conditions such as diabetes, hypertension, hyperlipidemia, diabetes, kidney disease, and liver disease. Malnutrition or nutritional disorders significantly increased the risk of ON (OR = 1.27, 95% confidence interval [CI] = 1.19\u20131.34), whereas concomitant isoniazid use decreased the risk (OR = 0.78, 95% CI = 0.72\u20130.86). (4) Conclusion: An increased risk of ON in patients with systemic diseases and nutritional deficiency was identified, whereas concomitant isoniazid use was associated with a decreased risk of ON. Patients with these risk factors should be carefully monitored to minimize the vision-threatening ON.<\/jats:p>","DOI":"10.3390\/toxics12080549","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T11:02:27Z","timestamp":1722337347000},"page":"549","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Risk Factors of Optic Neuropathy in Ethambutol Users: Interaction with Isoniazid and Other Associated Conditions of Toxic Optic Neuropathy"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7969-1419","authenticated-orcid":false,"given":"Jiyeong","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Pre-Medicine, College of Medicine, and Biostatistics Lab, Medical Research Collaborating Center (MRCC), Hanyang University, Seoul 04763, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4545-8344","authenticated-orcid":false,"given":"Seong Joon","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/ICU.0000000000000416","article-title":"Ethambutol optic neuropathy","volume":"28","author":"Chamberlain","year":"2017","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bjophthalmol-2012-301870","article-title":"Ethambutol-induced optic neuropathy: A nationwide population-based study from Taiwan","volume":"96","author":"Chen","year":"2012","journal-title":"Br. J. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10792-009-9293-z","article-title":"Risk factors for ethambutol optic toxicity","volume":"30","author":"Sadun","year":"2010","journal-title":"Int. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/WNO.0b013e31818e3c6b","article-title":"Incidence and clinical features of ethambutol-induced optic neuropathy in Korea","volume":"28","author":"Lee","year":"2008","journal-title":"J. Neuroophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5588\/ijtld.15.0275","article-title":"Incidence of toxic optic neuropathy with low-dose ethambutol","volume":"20","author":"Yang","year":"2016","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/0301-4738.77035","article-title":"Toxic optic neuropathy","volume":"59","author":"Sharma","year":"2011","journal-title":"Indian J. Ophthalmol."},{"key":"ref_7","unstructured":"Badrinath, M., Chen, P., and John, S. (2024). Isoniazid Toxicity. StatPearls, StatPearls Publishing."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/advances\/nmab033","article-title":"Vitamin B-6-Induced Neuropathy: Exploring the Mechanisms of Pyridoxine Toxicity","volume":"12","author":"Hadtstein","year":"2021","journal-title":"Adv. Nutr."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Parra, M., Stahl, S., and Hellmann, H. (2018). Vitamin B(6) and Its Role in Cell Metabolism and Physiology. Cells, 7.","DOI":"10.3390\/cells7070084"},{"key":"ref_10","first-page":"42","article-title":"Isoniazid and ethambutol as a cause of optic neuropathy","volume":"71","author":"Odel","year":"1987","journal-title":"Eur. J. Respir. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Baj, J., Forma, A., Kobak, J., Tyczynska, M., Dudek, I., Maani, A., Teresinski, G., Buszewicz, G., Januszewski, J., and Flieger, J. (2022). Toxic and Nutritional Optic Neuropathies-An Updated Mini-Review. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19053092"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1111\/acer.12468","article-title":"The prevalence of optic neuropathy in alcoholic patients\u2014A pilot study","volume":"38","author":"Daien","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_13","unstructured":"Margolin, E., Blair, K., and Shemesh, A. (2024). Toxic and Nutritional Optic Neuropathy. StatPearls, StatPearls Publishing."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.sjbs.2014.09.019","article-title":"Determination of potential role of antioxidative status and circulating biochemical markers in the pathogenesis of ethambutol induced toxic optic neuropathy among diabetic and non-diabetic patients","volume":"22","author":"Rasool","year":"2015","journal-title":"Saudi J. Biol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2314816","DOI":"10.1001\/jamanetworkopen.2023.14816","article-title":"Practice Patterns of Screening for Hydroxychloroquine Retinopathy in South Korea","volume":"6","author":"Kim","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.oret.2023.10.005","article-title":"Nationwide Usage of Pentosan Polysulfate and Practice Patterns of Pentosan Polysulfate Maculopathy Screening in South Korea","volume":"8","author":"Kim","year":"2024","journal-title":"Ophthalmol. Retin."},{"key":"ref_17","first-page":"952","article-title":"Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months","volume":"6","author":"Nolan","year":"2002","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_18","unstructured":"World Health Organization (2022). WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment\u2014Tuberculosis Care and Support, World Health Organization. WHO Guidelines Approved by the Guidelines Review Committee."},{"key":"ref_19","unstructured":"World Health Organization (2020). WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment\u2014Drug-Resistant Tuberculosis Treatment, World Health Organization. WHO Guidelines Approved by the Guidelines Review Committee."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2410677","DOI":"10.1001\/jamanetworkopen.2024.10677","article-title":"Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes","volume":"7","author":"Jorge","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lahoda Brodska, H., Klempir, J., Zavora, J., and Kohout, P. (2023). The Role of Micronutrients in Neurological Disorders. Nutrients, 15.","DOI":"10.3390\/nu15194129"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Baltrusch, S. (2021). The Role of Neurotropic B Vitamins in Nerve Regeneration. BioMed Res. Int., 2021.","DOI":"10.1155\/2021\/9968228"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.4103\/ijo.IJO_3746_20","article-title":"Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy","volume":"69","author":"Saxena","year":"2021","journal-title":"Indian J. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1001\/jama.1957.02980160012003","article-title":"Isoniazid as a cause of optic neuritis and atrophy","volume":"164","author":"Kass","year":"1957","journal-title":"J. Am. Med. Assoc."},{"key":"ref_25","first-page":"190","article-title":"Ethambutol is toxic to retinal ganglion cells via an excitotoxic pathway","volume":"40","author":"Heng","year":"1999","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1006\/taap.1999.8846","article-title":"Ethambutol-induced vacuolar changes and neuronal loss in rat retinal cell culture: Mediation by endogenous zinc","volume":"162","author":"Yoon","year":"2000","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.taap.2008.11.006","article-title":"Ethambutol-induced toxicity is mediated by zinc and lysosomal membrane permeabilization in cultured retinal cells","volume":"235","author":"Chung","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s10384-005-0308-7","article-title":"Leber\u2019s hereditary optic neuropathy precipitated by ethambutol","volume":"50","author":"Ikeda","year":"2006","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.mito.2009.11.004","article-title":"Ethambutol-induced optic neuropathy linked to OPA1 mutation and mitochondrial toxicity","volume":"10","author":"Guillet","year":"2010","journal-title":"Mitochondrion"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1442-9071.2010.02240.x","article-title":"Antituberculosis medication as a possible epigenetic factor of Leber\u2019s hereditary optic neuropathy","volume":"38","author":"Seo","year":"2010","journal-title":"Clin. Exp. Ophthalmol."}],"container-title":["Toxics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6304\/12\/8\/549\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:26:15Z","timestamp":1760109975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6304\/12\/8\/549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["toxics12080549"],"URL":"https:\/\/doi.org\/10.3390\/toxics12080549","relation":{},"ISSN":["2305-6304"],"issn-type":[{"value":"2305-6304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]}}}